Literature DB >> 7763061

Evidence for a superantigen mediated process in Kawasaki disease.

N Curtis1, R Zheng, J R Lamb, M Levin.   

Abstract

The clinical, pathological, and immunological similarities between Kawasaki disease and the staphylococcal and streptococcal toxic shock syndromes suggest that a superantigen toxin may be involved in the pathogenesis of the disease. The V beta repertoire of peripheral blood mononuclear cells from 21 children with Kawasaki disease, 28 children with other illnesses, and 22 healthy controls were examined using monoclonal antibodies to V beta 2, 5, 8, 12, and 19. The mean percentage of V beta 2 expressing T cells in the patients with Kawasaki disease was increased when compared with healthy controls or children with other illnesses. The mean percentages of V beta 5, 8, 12, and 19 expressing T cells were also increased in the patients with Kawasaki disease compared with healthy controls, but were not increased when compared with children with other illnesses. The selective use of V beta 2 supports the hypothesis that a superantigen is involved in the pathogenesis of Kawasaki disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7763061      PMCID: PMC1511234          DOI: 10.1136/adc.72.4.308

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  29 in total

1.  Cardiac sequelae of Kawasaki disease in Japan: statistical analysis.

Authors:  Y Nakamura; Y Fujita; M Nagai; H Yanagawa; Y Imada; S Okawa; T Kawasaki; H Kato
Journal:  Pediatrics       Date:  1991-12       Impact factor: 7.124

2.  Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes.

Authors:  L A Cone; D R Woodard; P M Schlievert; G S Tomory
Journal:  N Engl J Med       Date:  1987-07-16       Impact factor: 91.245

3.  Possible role for mite antigen In Kawasaki disease.

Authors:  K Furusho; T Ohba; T Soeda; K Kimoto; T Okabe; T Hirota
Journal:  Lancet       Date:  1981-07-25       Impact factor: 79.321

4.  Nationwide epidemic of Kawasaki disease in Japan during winter of 1985-86.

Authors:  H Yanagawa; Y Nakamura; T Kawasaki; I Shigematsu
Journal:  Lancet       Date:  1986-11-15       Impact factor: 79.321

5.  Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome.

Authors:  H Kato; S Koike; M Yamamoto; Y Ito; E Yano
Journal:  J Pediatr       Date:  1975-06       Impact factor: 4.406

6.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

7.  Kawasaki syndrome in the United States 1976 to 1980.

Authors:  D M Bell; D M Morens; R C Holman; E S Hurwitz; M K Hunter
Journal:  Am J Dis Child       Date:  1983-03

8.  Variant strain of Propionibacterium acnes: a clue to the aetiology of Kawasaki disease.

Authors:  H Kato; T Fujimoto; O Inoue; M Kondo; Y Koga; S Yamamoto; M Shingu; K Tominaga; Y Sasaguri
Journal:  Lancet       Date:  1983-12-17       Impact factor: 79.321

9.  Toxic-shock syndrome associated with phage-group-I Staphylococci.

Authors:  J Todd; M Fishaut; F Kapral; T Welch
Journal:  Lancet       Date:  1978-11-25       Impact factor: 79.321

10.  Polymerase activity in lymphocyte culture supernatants from patients with Kawasaki disease.

Authors:  J C Burns; R S Geha; E E Schneeberger; J W Newburger; F S Rosen; L S Glezen; A S Huang; J Natale; D Y Leung
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

View more
  38 in total

1.  Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research.

Authors:  P A Brogan; A Bose; D Burgner; D Shingadia; R Tulloh; C Michie; N Klein; R Booy; M Levin; M J Dillon
Journal:  Arch Dis Child       Date:  2002-04       Impact factor: 3.791

Review 2.  Overview of pharmacological treatment of Kawasaki disease.

Authors:  Z Onouchi; T Kawasaki
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  Familial Kawasaki disease and acute glomerulonephritis: case report and review of literature.

Authors:  Sarah A Salam Salih; Abdelbasit M A Elbashier; Nazik Abd Alaziz Alameen
Journal:  Sudan J Paediatr       Date:  2020

4.  Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease.

Authors:  K Matsubara; T Fukaya; K Miwa; N Shibayama; H Nigami; H Harigaya; H Nozaki; T Hirata; K Baba; T Suzuki; A Ishiguro
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

5.  Staphylococcus aureus isolates from patients with Kawasaki disease express high levels of protein A.

Authors:  E R Wann; A P Fehringer; Y V Ezepchuk; P M Schlievert; P Bina; R F Reiser; M M Höök; D Y Leung
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

6.  Mycoplasma infection and Kawasaki disease.

Authors:  C Leen; S Ling
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

Review 7.  Superantigens related to Kawasaki syndrome.

Authors:  D Y Leung
Journal:  Springer Semin Immunopathol       Date:  1996

Review 8.  Pharmacological therapy for patients with Kawasaki disease.

Authors:  R V Williams; L L Minich; L Y Tani
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

9.  Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD).

Authors:  Y Takata; S Seki; H Dobashi; S Takeshita; K Nakatani; Y Kamezawa; H Hiraide; I Sekine; S Yoshioka
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

10.  T cell activation profiles in Kawasaki syndrome.

Authors:  P A Brogan; V Shah; L A Clarke; M J Dillon; N Klein
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.